MannKind Corporation (NASDAQ: MNKD) saw its stock soar 10.86% in early trading on Wednesday following the release of its impressive third-quarter 2025 financial results and positive business updates. The biopharmaceutical company significantly outperformed analyst expectations, demonstrating robust growth and operational efficiency.

The company reported quarterly earnings of $0.07 per share, surpassing the analyst consensus estimate of $0.02 by a remarkable 233.33%. This represents a 16.67% increase compared to earnings of $0.06 per share in the same period last year. MannKind's quarterly sales reached $82.130 million, beating the analyst consensus estimate of $80.255 million by 2.34% and marking a 17.20% increase from $70.079 million in the previous year.

Adding to the positive momentum, MannKind announced that the FDA accepted for review the supplemental Biologics License Application (sBLA) for Afrezza in the pediatric population, with a PDUFA date set for May 29, 2026. The company also highlighted the recent completion of its acquisition of scPharmaceuticals, which is expected to diversify and accelerate MannKind's double-digit revenue growth. Furthermore, MannKind reported progress in its clinical trials, including the MNKD-101 Phase 3 global clinical trial for NTM treatment and the initiation of the MNKD-201 Phase 2 trial for IPF. These developments collectively contributed to the significant stock price increase, reflecting investor confidence in MannKind's growth trajectory and future prospects.